The symposium brings together social scientists, ethicists, scientists and clinicians to examine the scientific practices associated with the recent redefinition of the diagnostic criteria for Alzheimer’s disease and the concomitant emphasis on the need to identify and intervene in neurodegenerative processes at an earlier stage.

The symposium explores the boundary between the clinical and research uses of biomarkers and how the shifting boundary between laboratory and clinic and normal and pathological ageing changes how we study, care for and, as a society, approach Alzheimer’s disease.

Symposium sessions explore three key dimensions of the redefinition of Alzheimer’s disease, featuring empirical and theoretical papers presenting work conducted on Alzheimer’s disease and cognate areas.

  1. The ethical, legal and social implications of preclinical disease states
  2. The translational challenges of biomarker-based diagnostic criteria
  3. Biomarkers, the normal and the pathological

Confirmed speakers include:

Click here for registration information.

Organised by Richard Milne and Shirlene Badger (University of Cambridge) and Jason Karlawish (University of Pennsylvania). For more information, contact Richard Milne.


0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: